| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YGYNO.2015.07.008 |
| P698 | PubMed publication ID | 26166806 |
| P50 | author | Anil K. Sood | Q88114757 |
| Bradley J. Monk | Q107013145 | ||
| P2093 | author name string | Robert L Coleman | |
| Whitney Graybill | |||
| P2860 | cites work | Inflammation and cancer | Q24649640 |
| Revisiting the complexity of the ovarian cancer microenvironment--clinical implications for treatment strategies | Q26991951 | ||
| Regulation of Metastasis by microRNAs in Ovarian Cancer | Q26997006 | ||
| Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study | Q27853070 | ||
| Cancer statistics, 2014 | Q27861018 | ||
| Tumour-educated macrophages promote tumour progression and metastasis | Q29614307 | ||
| Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer | Q30424925 | ||
| Incorporation of pazopanib in maintenance therapy of ovarian cancer | Q33417673 | ||
| Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas | Q33587106 | ||
| Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. | Q33680309 | ||
| Notch3 pathway alterations in ovarian cancer. | Q33758223 | ||
| Therapeutic strategies for targeting the ovarian tumor stroma | Q33770035 | ||
| A phase 3 trial of bevacizumab in ovarian cancer | Q34030022 | ||
| CSF-1R inhibition alters macrophage polarization and blocks glioma progression | Q34993852 | ||
| Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. | Q35216301 | ||
| New ways to successfully target tumor vasculature in ovarian cancer | Q35928220 | ||
| Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy | Q36378276 | ||
| Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy | Q36414978 | ||
| OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer | Q36822179 | ||
| MicroRNA regulation in angiogenesis | Q37903456 | ||
| Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword? | Q37970070 | ||
| New biological treatments for gynecological tumors: focus on angiogenesis | Q38175506 | ||
| Tumor-associated macrophages: from mechanisms to therapy | Q38230880 | ||
| MiR-718 represses VEGF and inhibits ovarian cancer cell progression | Q38996307 | ||
| Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. | Q39689403 | ||
| Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice | Q40118539 | ||
| Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis | Q40191493 | ||
| The regulation of angiogenesis by tissue cell-macrophage interactions | Q42079591 | ||
| Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. | Q43048172 | ||
| Incorporation of bevacizumab in the primary treatment of ovarian cancer | Q44579933 | ||
| Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001. | Q46662920 | ||
| The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer. | Q53235546 | ||
| Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial | Q87460208 | ||
| Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial | Q88123697 | ||
| P433 | issue | 2 | |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 223-226 | |
| P577 | publication date | 2015-07-09 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer | |
| P478 | volume | 138 |
| Q38872239 | Anti-angiogenic agents in ovarian cancer: past, present, and future. |
| Q37739569 | Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells |
| Q58706801 | Antiangiogenesis therapy in ovarian cancer patients: An updated meta-analysis for 15 randomized controlled trials |
| Q38822258 | Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial |
| Q64232953 | Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment |
| Q47823943 | Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review. |
| Q47146356 | Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients. |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q58789499 | Targeting the Microenvironment in High Grade Serous Ovarian Cancer |
| Q39151484 | The development and use of vascular targeted therapy in ovarian cancer |
| Q50129142 | The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis |
Search more.